NasdaqGS - Delayed Quote USD
Exelixis, Inc. (EXEL)
At close: October 22 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Cash Flow
316,308.00
333,324.00
362,614.00
400,804.00
208,982.00
--
Investing Cash Flow
289,987.00
-26,955.00
-524,414.00
-42,884.00
-131,215.00
--
Financing Cash Flow
-872,316.00
-546,052.00
586.00
-14,801.00
-25,132.00
--
End Cash Position
198,459.00
262,994.00
502,677.00
663,891.00
320,772.00
--
Income Tax Paid Supplemental Data
--
185,658.00
127,870.00
12,960.00
4,115.00
--
Capital Expenditure
-150,019.00
-162,969.00
-138,456.00
-64,225.00
-30,345.00
--
Repurchase of Capital Stock
-875,833.00
-550,378.00
--
--
--
--
Free Cash Flow
166,289.00
170,355.00
224,158.00
336,579.00
178,637.00
--
12/31/2019 - 4/17/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
FOLD Amicus Therapeutics, Inc.
11.87
-1.17%
WVE Wave Life Sciences Ltd.
14.83
-1.85%
SMMT Summit Therapeutics Inc.
20.59
+0.44%
TGTX TG Therapeutics, Inc.
24.25
-0.49%
IOVA Iovance Biotherapeutics, Inc.
9.96
+0.40%
JAZZ Jazz Pharmaceuticals plc
113.10
-0.02%
CRNX Crinetics Pharmaceuticals, Inc.
59.61
+1.55%
ALNY Alnylam Pharmaceuticals, Inc.
296.48
+1.53%
TPST Tempest Therapeutics, Inc.
1.0500
0.00%
AXSM Axsome Therapeutics, Inc.
92.40
+0.98%